Adapted motivational interviewing to improve the uptake of treatment for glaucoma in Nigeria: study protocol for a randomized controlled trial

Trials

Jennifer Evans²  Jim McCambridge¹  Clare Gilbert²  Mohammed M Abdull³ 

[1] Department of Social and Environmental Health research, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, UK;Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK;Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Hospital Road, PMB 0117 Bauchi, Bauchi State, Nigeria

关键词: Randomized clinical trial;    Treatment adherence;    Blindness;    Africa;    Motivational interviewing;    Glaucoma;   

Others  :  806621
DOI  :  10.1186/1745-6215-15-149

 received in 2013-10-02, accepted in 2014-04-03,  发布年份 2014

【 摘 要 】

Background

Glaucoma is a chronic eye disease associated with irreversible visual loss. In Africa, glaucoma patients often present late, with very advanced disease. One-off procedures, such as laser or surgery, are recommended in Africa because of lack of or poor adherence to medical treatment. However, acceptance of surgery is usually extremely low. To prevent blindness, adherence to treatment needs to improve, using acceptable, replicable and cost-effective interventions. After reviewing the literature and interviewing patients in Bauchi (Nigeria) motivational interviewing (MI) was selected as the intervention for this trial, with adaptation for glaucoma (MIG). MI is designed to strengthen personal motivation for, and commitment to a specific goal by eliciting and exploring a person’s reasons for change within an atmosphere of acceptance and compassion. The aim of this study is to assess whether MIG increases the uptake of laser or surgery amongst glaucoma patients where this is the recommended treatment. The hypothesis is that MIG increases the uptake of treatment. This will be the first trial of MI in Africa.

Methods

This is a hospital based, single centre, randomized controlled trial of MIG plus an information sheet on glaucoma and its treatment (the latter being “standard care”) compared with standard care alone for glaucoma patients where the treatment recommended is surgery or laser.

Those eligible for the trial are adults aged 17 years and above who live within 200 km of Bauchi with advanced glaucoma where the examining ophthalmologist recommends surgery or laser. After obtaining written informed consent, participants will be randomly allocated to MIG plus standard care, or standard care alone. Motivational interviewing will be delivered in Hausa or English by one of two MIG trained personnel. One hundred and fifty participants will be recruited to each arm. The primary outcome is the proportion of participants undergoing laser or surgery within two months of the date given to re attend for the procedure. MIG quality will be assessed using the validated MI treatment integrity scale.

Discussion

Motivational interviewing may be an important tool to increase the acceptance of treatment for glaucoma. The approach is potentially scalable and may be useful for other chronic conditions in Africa.

Trial registration

ISRCTN79330571 (Controlled-Trials.com).

【 授权许可】

   
2014 Abdull et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90:262-267.
• [2]Abdull MM, Sivasubramaniam S, Murthy GVS, Gilbert C, Abubakar T, Ezelum C, Rabiu MM, on behalf of Nigeria National Blindness and Visual Impairment Study Group: Causes of blindness and visual impairment in Nigeria: the Nigeria National Blindness and Visual impairment survey. Invest Ophthalmol Vis Sci 2009, 50:4114-4120.
• [3]Kroese M, Burton H: Primary open angle glaucoma. The need for a consensus case definition. J Epidemiol Community Health 2003, 57:752-754.
• [4]Ashaye A, Ashaolu O, Komolafe O, Ajayi BG, Olusanya B, Adeoti C: Prevalence and types of glaucoma among an indigenous African population in southwestern Nigeria. Invest Ophthalmol Vis Sci 2013, 54:7410-7416.
• [5]Lee DA, Higginbotham EJ: Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005, 62:691-699.
• [6]Giorgis AT, Mulugeta A, Aga A, Deyassa N: The spectrum of glaucoma presentation at Menelik II Hospital. Addis Ababa Ethiop Med J 2012, 50:259-264.
• [7]Lawan A: Pattern of presentation and outcome of surgical management of primary open angle glaucoma in Kano. Ann Afr Med 2007, 6:180-185.
• [8]Omoti AE, Osahon AI, Waziri-Erameh MJ: Pattern of presentation of primary open-angle glaucoma in Benin City. Niger Trop Doct 2006, 36:97-100.
• [9]Mafwiri M, Bowman RJ, Wood M, Kabiru J: Primary open-angle glaucoma presentation at a tertiary unit in Africa: intraocular pressure levels and visual status. Ophthalmic Epidemiol 2005, 12:299-302.
• [10]Ntim-Amponsah CT: Visual loss in urban and rural chronic glaucoma patients in Ghana. Trop Doct 2002, 32:102-104.
• [11]Balo KP, Talabe M: Young glaucomatous patients in the Togo population. J Fr Ophtalmol 1994, 17:668-673. Article in French
• [12]The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000, 130:429-440.
• [13]Lam A, Seck C, Borzeix A, Faye M, Pintart D: Trabeculectomy in black Africans in primary open angle glaucoma. J Fr Ophthalmol 2000, 23:563-568.
• [14]Agbeja-Baiyeroju AM, Omoruyi M, Owoaje ET: Effectiveness of trabeculectomy on glaucoma patients in Ibadan. Afr J Med Med Sci 2001, 30:39-42.
• [15]Anand N, Mielke C, Dawda VK: Trabeculectomy outcomes in advanced glaucoma in Nigeria. Eye (Lond) 2001, 15:274-278.
• [16]Verrey JD, Foster A, Wormald R, Akuamoa C: Chronic glaucoma in northern Ghana a retrospective study of 397 patients. Eye (Lond) 1990, 4:115-120.
• [17]Rollnick S, Miller WR: What is motivational interviewing? Behav Cogn Psychother 1995, 23:325-334.
• [18]Burke BL, Arkowitz H, Menchola M: The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol 2003, 71:843-861.
• [19]Miller WR, Rollnick S: Motivational Interviewing, Helping People Change. 3rd edition. London: The Guilford Press; 2012.
• [20]Lundahl B, Moleni T, Burke BL, Butters R, Tollefson D, Butler C: Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials. Patient Educ Couns 2013, 93:157-168.
• [21]Miller WR, Yahne CE, Moyers TB, Martinez J, Pirritano MA: Randomized trial of methods to help clinicians learn motivational interviewing. J Consult Clin Psychol 2003, 72:1050-1062.
• [22]Mitcheson L, Bhavsar K, McCambridge J: Randomized trial of training and supervision in motivational interviewing with adolescent drug treatment practitioners. J Subst Abuse Treat 2009, 37:73-78.
• [23]Waterman H, Evans JR, Gray TA, Henson D, Harper R: Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev 2013., 4CD006132
• [24]Smedslund G, Berg RC, Hammerstrom KT, Steiro A, Leiknes KA, Dahl HM, Karlsen K: Motivational interviewing for substance abuse. Cochrane Database Syst Rev 2011., 5CD008063
• [25]La DT, Cahill K, Qin Y, Tang JL: Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010., 1CD006936
• [26]Cook PF, Bremer RW, Ayala AJ, Kahook MY: Feasibility of motivational interviewing delivered by a glaucoma educator to improve medication adherence. Clin Ophthalmol 2010, 4:1091-1101.
• [27]Lacey J, Cate H, Broadway DC: Barriers to adherence with glaucoma medications: a qualitative research study. Eye (Lond) 2009, 23:924-932.
• [28]Munder T, Wilmers F, Leonhart R, Linster HW, Barth J: Working Alliance Inventory-Short Revised (WAI-SR): psychometric properties in outpatients and inpatients. Clin Psychol Psychother 2010, 17:231-239.
• [29]Montreuil TC, Cassidy CM, Rovinovitch M, Pawliuk N, Schmitz N, Joober R, Malla AK: Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis. J Clin Psychopharmacol 2010, 32:465-469.
• [30]Wykes T, Rose D, Williams P, David AS: Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication. BMC Psychiatry 2013, 13:28. BioMed Central Full Text
• [31]Moyers T, Martin T, Manuel JK, Hendrickson SM, Miller WR: Assessing competence in the use of motivational interviewing. J Subst Abuse Treat 2005, 28:19-26.
• [32]Rotchford AP, Jayasawal R, Madhusudhan S, Ho S, King AJ, Vernon SA: Transscleral diode laser cycloablation in patients with good vision. Br J Ophthalmol 2010, 94:1180-1183.
• [33]Vernon SA, Koppens JM, Menon GJ, Negi AK: Diode laser cycloablation in adult glaucoma: long-term results of a standard protocol and review of current literature. Clin Exp Ophthalmol 2006, 34:411-420.
• [34]Ramrattan RS, Wolfs RC, Panda-Jones S, Jonas JB, Bakker D, Pols HA, Hofman A, de Jong PT: Prevalence and causes of visual field loss in the elderly and associations with improvement in daily functioning: The Rotterdam Study. Arch Ophthalmol 2001, 119:1788-1794.
• [35]Vistamehr S, Shelsta HN, Palmisano PC, Filardo G, Bashford K, Chaudhri K, Forster SH, Shafranov G, Shields BM: Glaucoma screening in a high-risk population. J Glaucoma 2006, 15:534-540.
• [36]Charalel RA, Lin HS, Singh K: Glaucoma screening using relative afferent pupillary defect. J Glaucoma 2014, 23:169-173.
• [37]Leske MC, Nemesure B, He Q, Wu SY, Fielding Hejtmancik J, Hennis A: Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology 2001, 108:1015-1022.
• [38]Foster PJ, Buhrmann R, Quigley HA, Johnson GJ: The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 2002, 86:238-242.